Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4276
iShares Global Clean Energy ETF
ICLN
$2.23B
| $196K | ﹤0.01% |
11,951
-10,201
| -46% | -$170K |
2020 Q1
23 quarters
|
|
4277
Patriot National Bancorp
PNBK
$117M
| $196K | ﹤0.01% |
107,513
+35,052
| +48% | +$48.4K |
2025 Q1
3 quarters
|
|
4278
EVI Industries
EVI
$248M
| $195K | ﹤0.01% |
7,900
+431
| +6% | +$10.7K |
2022 Q4
12 quarters
|
|
4279
Inhibikase Therapeutics
IKT
$279M
| $194K | ﹤0.01% |
94,795
+9,217
| +11% | +$14.7K |
2024 Q4
4 quarters
|
|
4280
Lifeway Foods
LWAY
$320M
| $194K | ﹤0.01% |
8,009
+659
| +9% | +$16.2K |
2023 Q4
8 quarters
|
|
4281
FT Vest US Equity Buffer & Premium Income ETF September
XISE
$32.6M
| $194K | ﹤0.01% |
6,381
+641
| +11% | +$19.4K |
2024 Q3
5 quarters
|
|
|
EWCZ
4282
DELISTED
European Wax Center
EWCZ
| $192K | ﹤0.01% |
53,398
+6,185
| +13% | +$23.1K |
2022 Q1
15 quarters
|
|
|
PTRN
4283
Pattern Group Inc
PTRN
$3.07B
| $192K | ﹤0.01% |
16,652
+3,352
| +25% | +$48.8K |
2025 Q3
1 quarter
|
|
|
SFBC
4284
Sound Financial Bancorp
SFBC
$119M
| $192K | ﹤0.01% |
4,402
+354
| +9% | +$15.8K |
2025 Q2
2 quarters
|
|
|
KGEI
4285
Kolibri Global Energy
KGEI
$221M
| $192K | ﹤0.01% |
48,822
+4,423
| +10% | +$19.2K |
2023 Q4
8 quarters
|
|
4286
Finance of America Companies
FOA
$124M
| $191K | ﹤0.01% |
7,907
+1,525
| +24% | +$34.7K |
2024 Q4
4 quarters
|
|
4287
FT Vest US Equity Moderate Buffer ETF June
GJUN
$516M
| $191K | ﹤0.01% |
4,828
-346
| -7% | -$13.5K |
2024 Q3
5 quarters
|
|
4288
2x Long VIX Futures ETF
UVIX
$191M
| $191K | ﹤0.01% |
1,674
+1,000
| +148% | +$183K |
2025 Q2
2 quarters
|
|
4289
Finward Bancorp
FNWD
$184M
| $190K | ﹤0.01% |
5,403
+541
| +11% | +$19K |
2024 Q3
5 quarters
|
|
4290
Algoma Steel
ASTL
$459M
| $190K | ﹤0.01% |
46,246
+45,877
| +12,433% | +$183K |
2022 Q1
15 quarters
|
|
4291
TaskUs
TASK
$739M
| $189K | ﹤0.01% |
16,052
-1
| -0% | -$13 |
2023 Q2
10 quarters
|
|
4292
Takeda Pharmaceutical
TAK
$57.1B
| $189K | ﹤0.01% |
12,137
+10,388
| +594% | +$149K |
2018 Q4
28 quarters
|
|
4293
Kiniksa Pharmaceuticals
KNSA
$5.91B
| $189K | ﹤0.01% |
4,577
-2,776
| -38% | -$111K |
2018 Q3
29 quarters
|
|
|
API
4294
Agora
API
$345M
| $187K | ﹤0.01% |
45,911
-7,000
| -13% | -$25.7K |
2022 Q1
15 quarters
|
|
4295
Evolution Petroleum
EPM
$144M
| $187K | ﹤0.01% |
52,739
+5,121
| +11% | +$21.6K |
2022 Q3
13 quarters
|
|
4296
Comp X International
CIX
$461M
| $186K | ﹤0.01% |
8,003
+245
| +3% | +$5.54K |
2017 Q3
33 quarters
|
|
4297
Ondas Inc
ONDS
$4.22B
| $184K | ﹤0.01% |
18,829
+18,406
| +4,351% | +$148K |
2025 Q2
2 quarters
|
|
4298
CALL
Shell
SHEL
$274B
| $184K | ﹤0.01% |
2,500
-350,100
| -99% | -$25.8M |
2025 Q3
1 quarter
|
|
|
RPT
4299
Rithm Property Trust
RPT
$86.3M
| $184K | ﹤0.01% |
11,071
+1,690
| +18% | +$26K |
2024 Q3
5 quarters
|
|
4300
Immix Biopharma
IMMX
$803M
| $183K | ﹤0.01% |
+35,000
| New | +$144K |
2025 Q4
0 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.